Enterprise Value

71.57M

Cash

46.67M

Avg Qtr Burn

-17.71M

Short % of Float

5.01%

Insider Ownership

7.72%

Institutional Own.

58.07%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 3

Data readout

Vidofludimus calcium (IMU-838) Details
Inflammatory bowel disease, Bowel disorder, Ulcerative colitis

Phase 2b

Update

IMU-856 Details
Celiac disease

Phase 2b

Initiation

Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 2

Data readout

Vidofludimus calcium (IMU-838) Details
COVID-19, Infectious disease

Phase 2

Update

Vidofludimus calcium (IMU-838) Details
Primary sclerosing cholangitis, Bile duct disease, Liver disease

Failed

Discontinued

Failed

Discontinued